125 related articles for article (PubMed ID: 7881035)
41. Energetic dysfunction in quinolinic acid-lesioned rat striatum.
Bordelon YM; Chesselet MF; Nelson D; Welsh F; Erecińska M
J Neurochem; 1997 Oct; 69(4):1629-39. PubMed ID: 9326292
[TBL] [Abstract][Full Text] [Related]
42. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.
Martínez-Serrano A; Björklund A
J Neurosci; 1996 Aug; 16(15):4604-16. PubMed ID: 8764649
[TBL] [Abstract][Full Text] [Related]
43. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model.
Lee ST; Chu K; Park JE; Lee K; Kang L; Kim SU; Kim M
Neurosci Res; 2005 Jul; 52(3):243-9. PubMed ID: 15896865
[TBL] [Abstract][Full Text] [Related]
44. Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density.
Masuo Y; Montagne MN; Pélaprat D; Scherman D; Rostène W
Brain Res; 1990 Jun; 520(1-2):6-13. PubMed ID: 2169955
[TBL] [Abstract][Full Text] [Related]
45. Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats.
Feng Q; Ma Y; Mu S; Wu J; Chen S; Ouyang L; Lei W
PLoS One; 2014; 9(3):e91512. PubMed ID: 24632560
[TBL] [Abstract][Full Text] [Related]
46. Acute intrastriatal injection of quinolinic acid provokes long-lasting misregulation of the cytoskeleton in the striatum, cerebral cortex and hippocampus of young rats.
Pierozan P; Gonçalves Fernandes C; Ferreira F; Pessoa-Pureur R
Brain Res; 2014 Aug; 1577():1-10. PubMed ID: 24976581
[TBL] [Abstract][Full Text] [Related]
47. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system.
Venero JL; Romero-Ramos M; Revuelta M; Machado A; Cano J
Brain Res; 1995 Feb; 672(1-2):153-8. PubMed ID: 7749737
[TBL] [Abstract][Full Text] [Related]
48. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
Ceresoli-Borroni G; Guidetti P; Schwarcz R
J Neural Transm (Vienna); 1999; 106(3-4):229-42. PubMed ID: 10392532
[TBL] [Abstract][Full Text] [Related]
49. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
Wenning GK; Granata R; Laboyrie PM; Quinn NP; Jenner P; Marsden CD
Mov Disord; 1996 Sep; 11(5):522-32. PubMed ID: 8866493
[TBL] [Abstract][Full Text] [Related]
50. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
Scattoni ML; Valanzano A; Popoli P; Pezzola A; Reggio R; Calamandrei G
Behav Brain Res; 2004 Jul; 152(2):375-83. PubMed ID: 15196806
[TBL] [Abstract][Full Text] [Related]
51. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types.
Figueredo-Cardenas G; Harris CL; Anderson KD; Reiner A
Exp Neurol; 1998 Feb; 149(2):356-72. PubMed ID: 9500958
[TBL] [Abstract][Full Text] [Related]
52. Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease.
Gianfriddo M; Corsi C; Melani A; Pèzzola A; Reggio R; Popoli P; Pedata F
Brain Res; 2003 Jul; 979(1-2):225-9. PubMed ID: 12850590
[TBL] [Abstract][Full Text] [Related]
53. A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis.
Ghorayeb I; Fernagut PO; Hervier L; Labattu B; Bioulac B; Tison F
Neuroscience; 2002; 115(2):533-46. PubMed ID: 12421620
[TBL] [Abstract][Full Text] [Related]
54. Striatal implants protect the host striatum against quinolinic acid toxicity.
Pearlman SH; Levivier M; Collier TJ; Sladek JR; Gash DM
Exp Brain Res; 1991; 84(2):303-10. PubMed ID: 1829685
[TBL] [Abstract][Full Text] [Related]
55. NMDA receptor overstimulation triggers a prolonged wave of immediate early gene expression: relationship to excitotoxicity.
Shan Y; Carlock LR; Walker PD
Exp Neurol; 1997 Apr; 144(2):406-15. PubMed ID: 9168840
[TBL] [Abstract][Full Text] [Related]
56. Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6-OHDA hemilesioned rat.
Olds ME; Jacques DB; Kpoyov O
Synapse; 2003 Jul; 49(1):1-11. PubMed ID: 12710010
[TBL] [Abstract][Full Text] [Related]
57. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
[TBL] [Abstract][Full Text] [Related]
58. Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.
Mishra J; Kumar A
Neurotox Res; 2014 Nov; 26(4):363-81. PubMed ID: 24752928
[TBL] [Abstract][Full Text] [Related]
59. Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Ryu JK; Kim SU; McLarnon JG
Exp Neurol; 2003 Oct; 183(2):700-4. PubMed ID: 14552912
[TBL] [Abstract][Full Text] [Related]
60. The phosphorylation status and cytoskeletal remodeling of striatal astrocytes treated with quinolinic acid.
Pierozan P; Ferreira F; Ortiz de Lima B; Gonçalves Fernandes C; Totarelli Monteforte P; de Castro Medaglia N; Bincoletto C; Soubhi Smaili S; Pessoa-Pureur R
Exp Cell Res; 2014 Apr; 322(2):313-23. PubMed ID: 24583400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
